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SUMMARY
The distribution ofthe Taq I polymorphism in the vitamin D receptor (VDR) gene and the MSc
1 polymorphism in thecollagen 1 alpha 1 (COL 1AI) gene were studiedin266female and55 male
patients attending an osteoporosis clinic. Allele frequency in control (T- or Z-score >-1.O) and
osteoporotic (T-orZ-scores<-2.5) groupswerecomparedusingChisquaredtests. Nodifferences
were found between the 2 groups with either ofthe polymorphisms. When allele frequency was
compared in patients with and without history of fracture, no differences were found in the
frequency ofthe COLlAl alleles. However there were significantly more fracture patients, who
had been previously treated with corticosteroids for other conditions, carrying the T allele ofthe
VDR polymorphism (X 2 = 5.65, p>O.01<0.02). In conclusion, neither ofthese polymorphisms aid
in the prediction of osteoporosis but the VDR T allele may carry an increased fracture risk in
patients who require corticosteroid treatment.
INTRODUCTION
Bone mineral density (BMD) is regulated by a
complexinteractionofgeneticandenvironmental
factors. Polymorphisms inthevitaminDreceptor
(VDR)andregulatoryregionofthetypeIcollagen
gene (COLIAI) have been associated with
decreased bone mass and increased risk of
osteoporoticfractures. Morrison' describedaTaq
I polymorphism in codon 352 of exon 9 of the
VDRgeneresultingfromaC-+Ttransition.Grant2
described a novel G--T polymorphism in the
regulatory region of the COLlAl gene which
was found to be strongly associated with low
BMD andincreasedriskofosteoporotic fracture.
We have studied the distribution of these two
polymorphisms in a group of people referred to
the osteoporosis clinic in Northern Ireland to
assess if there is any association between either
ofthese genotypes and low bone mineral density
(BMD) orthe risk ofosteoporotic fracture in our
local population.
METHODS
Patients
Patientsattendingtheosteoporosisclinicforbone
scans were studied. These patients had been
referred to the clinic for a variety of different
reasons e.g. family history, early menopause and
long term treatment with corticosteroids. The
bonedensity was measuredby dual energyX-ray
absorptiometry (DXA) using a Hologic4500A
bone densitometer. Lumbar spine (Ll-L4) and
total hip BMD were measured and T-scores and
Z-scores obtained. The local ethical committee
approved the study and patients gave informed
written consent. Blood was collected from 266
females (aged 28-83, median 64 years) and 55
males(aged22-75, median51 years). Allsubjects
were Caucasian and 62 ofthe females (23%) and
10 of the males (18%) had a family history of
osteoporosis. The BMD resultfrom the subject's
first visit was recorded and a blood sample sent
for gene studies. Atthe endofthe study (afterthe
Belfast City Hospital, Lisburn Road, Belfast BT9 7AB.
Department of Clinical Biochemistry:
E McClean,MSC, MRCPath, Consultant Clinical
Biochemist.
G P R Archbold, FRCP Glasg, FRCPath, Consultant
Pathologist.
Department of Elderly Care:
H McA Taggart, MD, FRCP, Consultant Physician in
Elderly Care.
Correspondence to Miss McClean
C) The Ulster Medical Society, 2003.Receptorpolymorphisms in osteoporosis
genotyping had been carried out) the patients
wereclassifiedastowhetherornottheyhadbeen
treated with corticosteroids, for other medical
conditions, and whether or not they had suffered
a low trauma fracture. Steroid treatment was
defined as .7.5mg for .6months and the
classification of a low trauma fracture was a
subjective assessment made by the doctor after
discussion with the patient.
DNA Isolation
Ten millilitres ofblood was collected from each
patient into tubes containing EDTA. The plasma
was removed and the DNA was extracted from
the white cells using the method ofJean Pierre.3
The DNA was dissolved in Tris-EDTA buffer
(1OmM)togiveaconcentrationofapproximately
250gg/mL and stored at -70°C until analysis.
Beforeanalysisthesamplesweredilutedto25[tg/
mL with double distilled, sterile water.
COLIAJ Genotyping
TheprimersusedwerethosedescribedbyGrant,2
namely a forward primer of 5'-
TAACITCTGGACTATTTGCGGACTfl'lTTGG-
3' and a reverse primer of 5'-
GTCCAGCCCTCATCCTGGCC-3'. Theprimers
were purchased from Gibco BRL, Life
Technologies, UK. Polymerase chain reaction
(PCR)wascarriedoutusingTaqDNApolymerase
(Boehringer Mannheim) under standard
conditions on a Perkin Elmer 2400 Thermal
Cycler. The thermal cycling protocol consisted
of35 cycles of94°C for 30 seconds, 63°C for 30
seconds and 72°C for 30 seconds with an initial
denaturing step of94°C for 3 minutes before the
first cycle and a final extension step of72°C for
7 minutes. The PCR product was incubated at
37°C with Msc I overnight (17 hours) and the
digests electrophoresed on a 1% agarose (Gibco
BRL, UK) plus 2.5% Nusieve (KMC Products,
UK)gelandstainedwithethidiumbromide. Wild
type DNA (G/G) has a single band at 255bp,
heterozygotes for the G-+T polymorphism have
twobands at237bp and255bp, andhomozygotes
forT/Thaveonebandat237bp.Thesecorrespond
to the SS, Ss and ss genotypes respectively.
Vitamin D Receptor Genotyping
The primers used were those described by
Morrison' namely a forward primer of 5'-
CAGAGCATGGACAGGGAGCAA-3' and a
reverse primer of 5'-
GCAACTCCTCATGGCTGAGGTCTC-3'. The
primers were purchased from Gibco BRL, Life
Technologies, UK. PCR was carried out using
Taq DNA polymerase (Gibco BRL) using
standard conditions on a Perkin Elmer 2400
Thermal Cycler. The protocol was 35 cycles of
94°C for 30 seconds, 63°C for 20 seconds and
72°C for 20 seconds with an initial denaturing
step of 94°C for 3 minutes and a final extension
step of72°C for7 minutes. The PCRproductwas
digested with Taqi for 2 hours at 65°C, the
digests electrophoresed on a 2% agarose gel and
stainedwithethidiumbromide. Homozygotesfor
the T nucleotide (TT) have two bands at 495bp
and 245bp, heterozygotes with C-4T (Tt) have
four bands at 495bp, 245bp, 290bp and 205bp
and homozygotes for the C (tt) nucleotide have
three bands at 290bp, 245bp and 205bp.
Statistics
The WHO criteria for defining patients with
ostoeporosis classifies those with T-score of
>-1.0as "normal", <-1.0->-2.5 as osteopenic and
< -2.5 as osteoporotic. The T-score compares the
BMD with that of the mean for a young adult
population. Since ourpopulation spanned such a
TABLE I
Summary ofgenotypes
No. of
Patients sstt ssTt ssTT Sstt SsTt SsTT SStt SSTt SSTT
f f f f f f f f f
Total population 314 0.6 1.6 0.3 4.8 14.3 9.2 8.6 33.1 27.4
All Females 261 0.8 1.9 0.4 5.0 14.9 8.4 9.2 32.6 26.8
All Males 53 0.0 0.0 0.0 3.8 11.3 13.2 5.7 35.8 30.2
f = frequency (%)
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TABLE II
Demographic details ofpatients, who have had no steroid treatment, when classified by
lumbar andhip T- and Z-scores
Females Males
Osteoporotic Osteopenic Control Osteoporotic Osteopenic Control
Lumbar T-score
Number 125 48 29 12 9 4
Age Range (years) 35-83 28-76 34-78 29-65 28-75 41-70
Median age (years) 63 64 58 46 41 66
Lumbar Z-score
Number 36 87 79 8 13 4
Age Range (years) 35-78 28-83 37-78 29-65 28-75 41-70
Median age (years) 64 63 64 52 44 66
Hip T-score
Number 61 91 48 2 13 10
Age Range (years) 35-83 28-81 34-75 39-59 29-75 28-70
Median age (years) 67 64 58 49 46 45
Hip Z-score
Number 11 72 117 1 11 13
Age Range (years) 35-76 28-83 34-81 39 29-75 28-70
Median age (years) 65 63 64 39 46 49
wide age group (28-83 years) we also classified
patients according to their Z-scores which
compares theirBMD with age-matched controls.
In order to be as comprehensive as possible we
used both the T-score and Z-score at both the
lumbar and hip sites to classify patients as those
with normal bone density, those who were
osteopenic, and those with osteoporosis. The
numbers in each group varied according the site
and scoring system used (Tables II and III).
Those with T or Z scores >-1.0 were regarded as
having normal bone density and were classified
as our "Control" group. The normal (or control),
osteopenic and osteoporotic groups were sorted
according to whether or not they had received
steroid therapy and whether or not they had
sustainedalowtraumafracture. TheChi-squared
test was used to compare the frequency of the S
with s and T with t alleles in patients who were
classified as "controls" (T- or Z- score >-1.0)
with those who were classified as "osteoporotic"
(T- or Z- score <-2.5) using both the lumbar and
hip BMO scans. Chi-squared was also used to
compare the frequency ofthe S, s, T and t alleles
inpatientswhohadsustainedalowtraumafracture
with those who had no history of fracture.
Results
Fifty females and 22 males had received steroid
therapy (.7.5mg for .6 months minimum).
Thirteenfemales and sevenmales wereuncertain
astowhetherornottheyhadreceivedasignificant
courseofsteroids.These20patientswereincluded
in the calculation of the overall genotype
frequency in the population (Table I) but were
not included when the patients were divided into
steroid and no steroid groups. There were no hip
scoresforfivefemalepatientsand,duetotechnical
difficulties with the assays, we were unable to
obtainCOL1A genotypesonfivepatientsamples
(4 females and 1 male) and VDR genotypes on
two patient samples (1 female and 1 male).
The numbers of patients classified as controls,
osteopenic and osteoporotic differed according
to whetherthey were classifiedaccording totheir
T-scoreorZ-score oraccordingtotheirlumbaror
hip scores (Tables II and III).
The genotype frequency in our total population
for the collagen Spl site ploymorphism was 69%
SS,28% Ss and3% ss, whichconforms toHardy-
Weinberg equilibrium. Females had the same
distribution but none of the males in our study
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TABLE III
Demographic details ofsteroid treatedpatients when classified by lumbar
andhip T- and Z- scores
Females Males
Osteoporotic Osteopenic Control Osteoporotic Osteopenic Control
Lumbar T-score
Number 29 16 5 12 9 1
Age Range (years) 35-81 35-83 36-60 28-68 22-73 41
Median age (years) 65 67 44 47 54 41
Lumbar Z-score
Number 7 17 26 10 9 3
Age Range (years) 50-61 35-74 36-83 28-66 22-73 41-61
Median age( years) 60 58 68 49 54 49
Hip T-score
Number 14 20 13 4 15 3
Age Range (years) 50-81 39-83 35-76 38-64 22-73 41-61
Median age (years) 63 66 60 52 51 52
Hip Z-score
Number 2 16 29 2 14 6
Age Range (years) 73-81 39-75 35-83 38-41 22-69 41-73
Median age (years) 77 59 68 40 53 53
hadthe ss genotype, with 72% being SS and 28%
being Ss. The genotype frequency of the Taq I
polymorphism in ourpopulation is 37% TT, 49%
Ttand 14%tt,whichconformstoHardy-Weinberg
equilibrium. The frequency in the female
population was 36% TT, 49% Tt and 15% tt and
inthemalepopulationitwas43% TT,47% Ttand
10% tt. Due to the small numbers in some ofthe
genotypes (especially the ss genotype ) it was not
possible to apply statistical methods to the
individual or combined genotypes. When Chi
squared tests were applied to the numbers of
patients bearing the S or s and the T or t allele in
the control groups and osteoporotic groups there
was no significant difference between them,
whether they were classified by lumbar orhip T-
or Z- score. One hundred females and 26 males
had a history of fracture. The T allele was more
prevalent in patients with a history of fracture
(x2=5.05, p>0.02<0.05). This trend was evident
in the steroid treated group (X2=5.65, p>0.01
<0.02), but not in the no steroid group (Figs. 1 &
2). There was no difference in the frequency of
the S or s allele in patients with a history of
fracture.
DISCUSSION
Osteoporosis is the most common metabolic
disease. It is a disease in which the density or
mass of the bone is reduced, leading to an
increased risk of fracture. The ability to predict
andpreventosteoporotic-related fractures would
beofmajorbenefittobothpatientandNHS. Thus
finding a biochemical or genetic marker which
could predict those at greatest risk ofdeveloping
osteoporosis is an attractive proposition. To date
none ofthe biochemical markers have proved of
any value in diagnosing osteoporosis, although
they have their uses in monitoring the effects of
treatment. The early reports on the COLlAl Spl2
and vitamin D receptor Taq 11 polymorphisms
appeared hopeful of being able to correlate
genotype with bone density and risk of fracture.
However subsequent studies with both these
polymorphismshavebroughtconflictingreports.
Incontrasttomanypreviousstudies 2,4-7wefound
no significant difference in the distribution of
genotypes for the COLlAI genotypes in the
osteoporosisandcontrolgroupsoranyassociation
between genotype and fracture. Other studies 8-11
report similar results to ourselves with no
C) The Ulster Medical Society, 2003.
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Fig I VDR genotype in patients who had not been previously treated with corticosterolds
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associationbetweenCOL1Al genotypeandeither
BMD or fracture. Beaven12 has reported ethnic
differences intheprevalenceofthe s allele, being
lower in an African and Asian population than in
European countries and Han et all3 have found
the Spl polymorphism to be absent in a Korean
population. However, all the studies mentioned
abovewhichfoundapositiveassociationbetween
thepolymorphismandBMDorfractureriskwere
carriedoutwithCaucasianEuropeanorAmerican
subjects, so racial differences are unlikely to be
the reason for the disparity in the findings. In
most cases the distribution ofthe genotypes was
similartooursinthenon-osteoporoticpopulation;
it was in the osteoporotic group that the
distributionofthegenotypesdifferedinthestudies
which had positive findings. The criteria used to
choose the patient group may be the key to the
differences in the findings ofthe various studies.
Utterlinden'4whoseoveralldistributionwasvery
similar to ours, only found genotype related
differences inthebonemineral density in women
in the 75-80 year old age group, younger groups
showed no difference between the genotypes.
Since our study spanned a wide age range any
differences in the oldest patients may have been
diluted by the younger patients. (We did not
pursue this possibility since, if genotyping is to
be of any use in a clinical situation it would be
veryimportantthattheriskofosteoporosis could
be identified in young patients, before clinical
osteoporosis is evident.) A recent study by
Brown15 foundthe association betweenCOLlAl
polymorphism and the rate oflumbar spine bone
loss to be dependent on dietary calcium. Carriers
ofthe "s"allele lostmoreboneinthelowcalcium
intake group but the carriers ofthe "S" allele lost
more bone in those with a high calcium intake.
Since our patients were chosen at random from
patients attending the Osteoporosis Clinic it is
likely thatthey spanned arange from low to high
calcium intake.
We found no association between the Taq I
polymorphism genotype and BMD as assessed
bybothT-scoreandZ-scorewhichagaincontrasts
with some ofthe earlier studies" 1-6 but confirms
otherstudies.'7-19A meta-analysisof16published
papers20 showedgreatdisparity between studies,
with somefinding an association between the TT
genotype and lower BMD, some finding an
association between the tt genotype and lower
BMD and others finding no association. Marked
racial difference in the distribution of the
genotypes have been reported.'7 21 22 We found
no over-representation ofany genotype in either
oursteroidornosteroidgroupswithosteoporosis.
However the TT genotype was over-represented
in patients who had been treated with
corticosteroids and who had sustained a low
trauma fracture (56% in the fracture population
compared to 30% in the control population).
Moststudieshaveexcludedcorticosteroidtreated
patients from their study population but one
Australian study23 which looked specifically at
patients who were on corticosteroids for various
diseases, like ourselves, failed to find any
associationbetweenBMDandVDRgenotypes at
any site. A preliminary study by Chamberlain,24
inaUKpopulation, foundanover-representation
of the TT genotype in corticosteroid treated
patients who had very low BMD or evidence of
vertebral fracture.
Osteoporosis is a major side-effect of steroid
therapy but some individuals do not develop
osteoporosis. It is possible that the susceptibility
to steroid induced osteoporsois is genetically
modified. Glucocorticoids influence the
regulation ofcalcium and phosphate metabolism
and inhibit vitamin D -mediated induction of
genes in osteoblasts 25 so polymorphisms or
mutations in the vitamin D receptor may be one
ofthe factors involvedin how individuals handle
their treatment. Our study suggests that the TT
genotype may be a risk factor for fractures in
patients treated with glucocorticoids. However
40% of patients with a fracture history were Tt
and4% werettsofurtherstudiesonlargenumbers
ofpatients with steroid-induced osteoporosis are
required.
Due to the small number of people with the ss
genotype it was not feasible to compare people
withthe two "highrisk" genotypes (ie ss andTT)
with the seemingly "low risk" genotypes (ie SS
and tt). One female had the ssTT genotype. Her
lumbar and hip T-scores were -3.47 and -1.78
and Z-scores were -1.42 and -0.1 1 respectively,
she had no familyhistory ofosteoporosis but had
had a low trauma fracture. The most frequent
genotype in our population was SSTt (Table I)
andthiswasconsistentinallthegroupsofpatients
except the steroid treated patients with a history
offracture, inwhich SSTT was the most common
genotype. This probably reflects our findings
with the VDR receptor genotypes rather than a
synergistic or additive effect of the two types of
polymorphism. The number with the SsTt
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genotype was considerably less in patients with
fractures than those without fractures but the
numbers were too small to draw any definite
conclusions. Further investigation with larger
numbers ofpatients may reveal more significant
differences between the genotypes but for a
genetic test to be of value in diagnosis or risk
stratificationoneortwogenotypes wouldhaveto
stand out in the patient group, even in small
numbers ofpatients.
In conclusion, we have been unable to present
any evidence that either COLlAI or VDR
genotyping, singly or together, have a role in
predicting either risk of osteoporosis or risk of
fracture.
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